Evidence map›Paper›PMID 39399553›Full record

ArticleNeurology. Clinical practice2025

Efficacy and Tolerability of Anti-CGRP Monoclonal Antibodies in Patients Aged ≥ 65 Years With Daily or Nondaily Migraine.

Amira Salim, Sudipa Biswas, Claire Sonneborn, Olivia Hogue, Elise Hennessy, Maryann Mays, Aarushi Suneja, Zubair Ahmed, Ignacio F Mata

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology. Clinical practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. The Neurology of Menopause.Current neurology and neuroscience reports · 2026
    Review
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Amira SalimDepartment of Molecular Medicine (A. Salim), Cleveland Clinic Lerner College of Medicine, Case Western Reserve University; Genomic Medicine Institute (A. Salim, IFM), Lerner Research Institute, Cleveland Clinic; Center for Neurological Restoration (SB, MM, A. Suneja, ZA), Cleveland Clinic Neurological Institute; Quantitative Health Sciences (CS, OH), Lerner Research Institute, Cleveland Clinic, OH; and Neuroscience Institute (EH), Penn State Health Milton S. Hershey Medical Center, Hershey, PA.ORCID https://orcid.org/0000-0001-5300-3983
Sudipa BiswasDepartment of Molecular Medicine (A. Salim), Cleveland Clinic Lerner College of Medicine, Case Western Reserve University; Genomic Medicine Institute (A. Salim, IFM), Lerner Research Institute, Cleveland Clinic; Center for Neurological Restoration (SB, MM, A. Suneja, ZA), Cleveland Clinic Neurological Institute; Quantitative Health Sciences (CS, OH), Lerner Research Institute, Cleveland Clinic, OH; and Neuroscience Institute (EH), Penn State Health Milton S. Hershey Medical Center, Hershey, PA.ORCID https://orcid.org/0009-0001-2148-6551
Claire SonnebornDepartment of Molecular Medicine (A. Salim), Cleveland Clinic Lerner College of Medicine, Case Western Reserve University; Genomic Medicine Institute (A. Salim, IFM), Lerner Research Institute, Cleveland Clinic; Center for Neurological Restoration (SB, MM, A. Suneja, ZA), Cleveland Clinic Neurological Institute; Quantitative Health Sciences (CS, OH), Lerner Research Institute, Cleveland Clinic, OH; and Neuroscience Institute (EH), Penn State Health Milton S. Hershey Medical Center, Hershey, PA.ORCID https://orcid.org/0000-0003-3038-5418
Olivia HogueDepartment of Molecular Medicine (A. Salim), Cleveland Clinic Lerner College of Medicine, Case Western Reserve University; Genomic Medicine Institute (A. Salim, IFM), Lerner Research Institute, Cleveland Clinic; Center for Neurological Restoration (SB, MM, A. Suneja, ZA), Cleveland Clinic Neurological Institute; Quantitative Health Sciences (CS, OH), Lerner Research Institute, Cleveland Clinic, OH; and Neuroscience Institute (EH), Penn State Health Milton S. Hershey Medical Center, Hershey, PA.ORCID https://orcid.org/0000-0002-3985-3831
Elise HennessyDepartment of Molecular Medicine (A. Salim), Cleveland Clinic Lerner College of Medicine, Case Western Reserve University; Genomic Medicine Institute (A. Salim, IFM), Lerner Research Institute, Cleveland Clinic; Center for Neurological Restoration (SB, MM, A. Suneja, ZA), Cleveland Clinic Neurological Institute; Quantitative Health Sciences (CS, OH), Lerner Research Institute, Cleveland Clinic, OH; and Neuroscience Institute (EH), Penn State Health Milton S. Hershey Medical Center, Hershey, PA.ORCID https://orcid.org/0000-0003-2128-632X
Maryann MaysDepartment of Molecular Medicine (A. Salim), Cleveland Clinic Lerner College of Medicine, Case Western Reserve University; Genomic Medicine Institute (A. Salim, IFM), Lerner Research Institute, Cleveland Clinic; Center for Neurological Restoration (SB, MM, A. Suneja, ZA), Cleveland Clinic Neurological Institute; Quantitative Health Sciences (CS, OH), Lerner Research Institute, Cleveland Clinic, OH; and Neuroscience Institute (EH), Penn State Health Milton S. Hershey Medical Center, Hershey, PA.ORCID https://orcid.org/0000-0002-6957-4219
Aarushi SunejaDepartment of Molecular Medicine (A. Salim), Cleveland Clinic Lerner College of Medicine, Case Western Reserve University; Genomic Medicine Institute (A. Salim, IFM), Lerner Research Institute, Cleveland Clinic; Center for Neurological Restoration (SB, MM, A. Suneja, ZA), Cleveland Clinic Neurological Institute; Quantitative Health Sciences (CS, OH), Lerner Research Institute, Cleveland Clinic, OH; and Neuroscience Institute (EH), Penn State Health Milton S. Hershey Medical Center, Hershey, PA.ORCID https://orcid.org/0009-0001-7081-5737
Zubair AhmedDepartment of Molecular Medicine (A. Salim), Cleveland Clinic Lerner College of Medicine, Case Western Reserve University; Genomic Medicine Institute (A. Salim, IFM), Lerner Research Institute, Cleveland Clinic; Center for Neurological Restoration (SB, MM, A. Suneja, ZA), Cleveland Clinic Neurological Institute; Quantitative Health Sciences (CS, OH), Lerner Research Institute, Cleveland Clinic, OH; and Neuroscience Institute (EH), Penn State Health Milton S. Hershey Medical Center, Hershey, PA.
Ignacio F MataDepartment of Molecular Medicine (A. Salim), Cleveland Clinic Lerner College of Medicine, Case Western Reserve University; Genomic Medicine Institute (A. Salim, IFM), Lerner Research Institute, Cleveland Clinic; Center for Neurological Restoration (SB, MM, A. Suneja, ZA), Cleveland Clinic Neurological Institute; Quantitative Health Sciences (CS, OH), Lerner Research Institute, Cleveland Clinic, OH; and Neuroscience Institute (EH), Penn State Health Milton S. Hershey Medical Center, Hershey, PA.ORCID https://orcid.org/0000-0003-1198-0633

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Objectives: Despite decreasing prevalence of migraine with advancing age, there remains a significant proportion of individuals aged ≥65 years with migraine. Treatment of this population is difficult and they are often excluded from clinical trials, limiting evidence regarding migraine treatment outcomes. Our objective is to assess the efficacy and tolerability of anti-calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb) therapies (erenumab, fremanezumab, and galcanezumab) in patients ≥65 years (O65) compared with patients <65 (U65) with daily or nondaily migraine. Methods: This observational study uses retrospective data from the electronic medical records of patients who were treated with an anti-CGRP mAb between June 2018 and November 2021. Efficacy was determined through a reduction in monthly migraine days (MMDs) and Headache Impact Test (HIT-6) scores from baseline to posttreatment. Tolerability was examined through the number of adverse events reported per group. Mann-Whitney tests were used to compare the efficacy and tolerability of U65 and O65 patients overall and separated into daily and nondaily migraine groups. Results: The dataset consisted of U65 (n = 2,707; median [interquartile range]; 45.4 [35.8-53.8] years) or O65 (n = 304; 69.5 [67.3-73.3] years) and further separated into daily (n = 1,303) and nondaily (n = 1,708) migraine. There was no difference ( Discussion: This retrospective analysis provides real-world evidence that there is no difference in the efficacy and tolerability of treatment with erenumab, fremanezumab, and galcanezumab in patients O65 when compared with patients U65 both with daily or nondaily migraine. These data may help guide the choice of migraine treatment in older populations.

Identifiers

PMID39399553
PMCPMC11464238

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.